Summary of Hyperkalemic Periodic Paralysis

Submitted by deb on Tue, 06/28/2011 – 21:14

Clinical Signs

Hyperkalemic Periodic Paralysis is a genetically determined disorder which causes attacks of weakness and flaccid paralysis. Attacks last from 10 min to 1 hour, very rarely up to 1-2 days. Some patients experience only a few attacks over their lifetime, others have attacks every day. Diagnosis is suggested by attacks of weakness during which the patient’s serum potassium is above 5.0 mmol/l or rises at least .5 of a mmol/l above their normal level when not in an attack.

During attacks sodium moves into the muscles, which may cause a fall in serum sodium levels. Water also moves into the cell causing further hyperkalemia. Hyperregulation may occur at the end of an attack causing hypokalemia, which may result in a misdiagnosis of hypokalemic PP.  At the end of an attack the patient may produce a large amount of dilute urine containing increased creatine and experience an increase in CK. Between attacks the serum potassium is within normal limits and strength returns to normal, but there may be mild muscle stiffness. 

Symptoms usually develop in the first years of life, but invariably begin by age 20. Attacks often occur in the early morning following exercise or a meal of potassium-rich food, especially if the patient has been chilled or is under stress. Attacks occur infrequently to begin with, become more frequent in the 30s and may cease by the time the patient is in their 50s, sometimes to be replaced by permanent muscle weakness.


Hyperkalemic periodic paralysis occurs as a result of a mutation in the alpha subunit of the Sodium Channel – (SCN4A); Gene Map Locus 17q23.1-q25.3;

Ten Mutations or sequence variants have been identified. Mutations Thr704Met, Met1592Val and Ile693Thr are responsible for 98% of identified cases to date. Mutations Ala1156Thr; Met1592Val, Phe1490Leu, Met1493Ile, Ile693Thr, Ile1495Phe, Ser246Leu, Thr323Met and Leu689Ile are responsible for the remaining two percent of cases.

Mutations Arg1448Ser, Arg1448Cys, Arg1448His, and Arg1448Pro are found in HyperKPP patients who also have Paramyotonia Congenita. Met1360Val caused PMC in one family member and HyperKPP in other family members. Thr704Met and Met1592Val have also been identified as causing PMC in single families.

Genetic-Clinical Correlations:

Patients with mutation Thr704Met  often develop permanent weakness.  Patients with Met1592Val  have myotonia; Ala1156Thr & Met1360Val: Reduced penetrance (unaffected carriers can pass gene to next generation.)

Family History:

Autosomal dominant inheritance (Statistically 50% of an affected person’s offspring will inherit). Age at onset: Infancy to second decade of life. All who inherit the most common genes develop symptoms (complete penetrance) but severity is very variable. There is reduced penetrance with mutations A1156T & M1360V. 

Cardiac Signs and Emergency Treatment of an Attack

For severe hyperkalemia or weakness – inpatient with cardiac monitoring. Mild hyperkalemia or weakness – outpatient with close follow up. Be alert to possible complications: Cardiac arrhythmias, respiratory collapse. May need respiratory support.

Institute emergency treatment if EKG changes occur or serum K > = 7 mEq/L. EKG change sequence: tall peaked T waves, diminished R waves amplitude, increased QRS or PR intervals and P wave disappearance. Slow infusion (over 5 min) of 10% calcium gluconate (reduces cardiac sensitivity to hyperkalemia). Sodium bicarbonate i.v. infusion to raise pH (lower H+) thereby lowering K+ via intracellular shift of H+ and K+ ions (H+ and K+ go in same direction). Infusion of 1 mg/kg D50W containing regular insulin 0.5- 1.0 unit/ml (drives K+ into cells).

Patients’ Descriptions of Hyperkalemic Symptoms & Episodes Typically Include:

Weakness or paralytic attacks which may come on very rapidly. Falls may occur in sudden attacks. Rest after activity is a common trigger. Changes in the daily level of activity and periods of inactivity (sleep, sitting through a movie, car or plane trip, especially in cool temperatures) triggers weakness in many patients. Being outside on a cool windy day can bring on facial tightness and a characteristic “grimace”, with an inability to smile and narrowed eyes. Photo is of a 65 year-old man with HyperKPP/PMC outside on a November day, trying to smile. Many patients learn to move constantly to avoid weakness. Some patients find that chewing gum is enough “activity” to stave off weakness.

Patients may describe muscle stiffness (myotonia) which can be ‘worked’ or ‘walked’ off. Myotonia is often dismissed as rheumatism, arthritis or fibromyalgia. High carbohydrate food (candy bar) or drink (sugar cola, sweet tea) taken at the first sign of weakness may abort or relieve episodes.

HyperKPP may be accompanied by Paramyotonia Congenita von Eulenburg. This may mean that the patient’s serum potassium is labile during attacks, and paradoxical myotonia may be a prominent feature of attacks. Paradoxical myotonia is myotonia which worsens with activity, with little to no electrical evidence of myotonia. Aggressive lowering of potassium may precipitate attacks of paramyotonia. 

Diagnosis of HyperKPP Genetic Testing

Genetic Testing for identified mutations is available through a number of commercial laboratories, but not all mutations have been identified yet, so a negative DNA test does not rule out HyperKPP.

CMAP amplitude Test: Positive in 80% of HyperKPP patients

The CMAP test is easier on patients than provocative tests and is almost specific for periodic paralysis. The test is conducted by measuring the CMAP in hypothenar muscle by means of surface electrodes. The test takes approximately 45 minutes and is non-invasive. Patient must be medication-free, i.e. no K+, K+ wasting diuretics, CAI inhibitors, mexitiline, etc. for 72 hours prior to test. CMAP amplitude: Increased immediately after sustained (5 min) maximal contraction Progressively reduced (by 40%) during rest 20 to 40 min after initial increment In Normals: Mildly increased CMAP amplitude after exercise

Provocative Testing: Oral K+ load only if renal, cardiac function and serum K+ are normal (never if arrhythmic). Perform fasting, in am, after exercise 0.05 g/kg KCl in sugar-free liquid over 3 minutes. If negative may give 0.10 to 0.15 g/kg KCl, monitor electrolytes, EKG & strength every 20 minutes. Weakness is typically most noticable after 90 to 180 minutes. IV glucose loading does not provoke weakness in HyperKPP but K+ loading tests (0.05 to .15 g/kg) will induce weakness. K+ loading tests are potentially hazardous and are contraindicated in patients with renal disease and diabetes. Patients should be screened for Andersen-Tawil Syndrome before provocative testing begins. Random serum K+ measurements may suggest the diagnosis, since K+ elevations are frequent during attack-free intervals. EMG evidence of myotonia and finding of vacuoles on muscle biopsy provide supporting data.

Management and Therapy of HyperKPP

The goals of treatment are relief of acute symptoms and prevention of further attacks. Attacks of HyperKPP are brief and seldom severe enough to require emergency treatment. However, progressive permanent weakness can occur with repeated attacks, so treatment should occur as soon as possible.


A high-carbohydrate diet, which avoids food rich in potassium, may be recommended. Glucose or other carbohydrates given during an attack may reduce the severity. Patients can be counseled to drink a sweetened beverage at the first sign of an attack.

To Treat Weakness in HyperKPP

Hydrochlorothiazide (25 to 75 mg/day) Acetazolamide (125 to 1,000 mg/d) Dichlorphenamide (50 to 150 mg/day) Albuterol by inhaler or motor-driven nebulizer; Calcium gluconate syrup 15 ml dissolved in sweet tea may serve to abort developing attacks. It is often advisable to prevent hyperkalemic attacks of weakness by the continuous use of a thiazide diuretic or acetazolamide. Thiazide diuretics are preferable because of the possible complications of acetazolamide therapy. The dosage should be kept as low as possible (e.g., 25 mg hydrochlorothiazide daily or every other day). In severe cases, 50 mg or 75 mg of hydrochlorothiazide should be taken daily very early in the morning. Individuals should be monitored so that the serum potassium concentration does not fall below 3.3 mmol/L or the serum sodium concentration below 135 mmol/L

To Treat Muscle stiffness Mexiletine 100 to 1,000 mg/day; Paxil 20 mg day;

To Treat Paramyotonia ( PMC): Mexiletine 100 to 1,000 mg/day, Paxil 20 mg daily, Potassium supplementation as required 5-10 mEq 

Other Considerations Andersen-Tawil Syndrome

Andersen’s Syndrome is a distinct periodic paralysis occurring in the setting of either hyper- or hypokalemia, with severe cardiac involvement (LQT) and skeletal abnormalities. Every patient with periodic paralysis must be screened for this potentially lethal condition. Partial manifestations are common and the subtle nature of the cardiac and dysmorphic features may delay diagnosis but clinical recognition of this syndrome is vital given the predisposition for dysrhythmias and sudden death. Cardiac evaluations using serial ECGs with measurements of the QTc interval are essential and should be performed on all patients undergoing workup for periodic paralysis before provocative tests are performed.

Malignant Hyperthermia in Hyperkalemic PP

Periodic Paralysis patients are at increased risk to this Malignant Hyperthermia. During surgery, avoid use of depolarizing anesthetic agents including suxamethonium and anticholinesterases that increase myotonia, which can result in masseter spasm and stiffness of respiratory and other skeletal muscles, and interfere with intubation and mechanical ventilation.


1. Barch R, Furman RE: Pathophysiology of myotonia and periodic paralysis. In: Asbury AK, McKhann GM,

2 McDonald WI, eds. Diseases of the Nervous System, Clinical Neurobiology. 2nd Ed. Philadelphia, W.B. Saunders Co., 1992

3. Ptacek LJ, Griggs RC: Periodic paralysis. In: Isselbacher KJ, Wilson JD, et al, eds. Harrison’s Principles of Internal Medicine. 13th Ed. New York, McGraw Hill, 1994

4. Bendahhou S; Cummins TR; Hahn AF; et al; A double mutation in families with periodic paralysis defines new aspects of sodium channel slow inactivation. J Clin Invest 106:431-8, 2000

5. Sterns RH, Narins RG: Disorders of potassium balance. In: Stein JH, ed. Internal Medicine. 4th Ed. Boston, Little Brown & Co, 1994

6. Hoffman EP: Voltage-gated ion channelopathies: inherited disorders caused by abnormal sodium, chloride, and calcium regulation in skeletal muscle. Annual Review of Medicine 1995;46:431-441

7. Lehmann-Horn F, Rudel R, Jurkat-Rott K. Non-dystrophic myotonias and periodic paralyses. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. 3 ed. New York: McGraw-Hill; 2004:1257-300.

8. Brooke M. H.; Disorders of Skeletal Muscle. Neurology in Clinical Practice, Third Edition, Bradley, W.G.; Daroff, R.B.; Fenichel G.M. & Marsden, D.C.: Eds. Boston, MA: Butterworth/Heinemann. 2000

9. Doyle D. John; Emergency treatment of Hyperkalemia; Critical Care Medicine 1980 8:562-569 Neuromuscular Disease Center, Washington Univ school of Medicine, St. Louis, Mo. 2002

10. Mendell, Griggs, Ptacek in Harrison’s ‘Principles of Internal Medicine’ 14th ed. 1998, Chap 14 Levitt, L. P.; Rose, L. I.; Dawson, D. M. : Hypokalemic periodic paralysis with arrhythmia. New Eng. J. Med. 286: 253-254, 1972

11. Sansone, V.; Griggs, R. C.; Meola, G.; et al: Andersen’s syndrome: a distinct periodic paralysis. Ann. Neurol. 42: 305-312, 1999

12. Kuntzer T, Flocard F, Vial C, Kohler A, Magistris M; et al: Muscle Nerve 2000 Jul;23(7):1089-94: Exercise test in muscle channelopathies and other muscle disorders.

13. McManis PG; Lambert EH; Daube JR: The exercise test in periodic paralysis. Muscle Nerve, 1986 Oct, 9:8, 704-10

14. Katz JS; Wolfe GI; Iannaccone, S; et al: The Exercise Test in Andersen Syndrome; Archives of Neurology / volume:56 (page: 352)

15. Abbott GW; Butler MH; Bendahhou S; et al; MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell 104:217-31, 2001

16. Kuzmenkin A, Jurkat-Rott K, Lehmann-Horn F, Mitrovic N.; Impaired slow inactivation due to a polymorphism and substitutions of Ser-906 in the II-III loop of the human Nav1.4 channel. Pflugers Arch. 2003 Oct;447(1):71-7. Epub 2003 Jul 26. PMID: 12898257

17. Richard T. Moxley III, MD, Channelopathies; Current Treatment Options in Neurology 2000, 2:31-47. Current  Medicine  Group  LLC ISSN 1092-8480